中枢神经系统的原发性恶性肿瘤占成人所有癌症的 2%，占 15 岁以下儿童的近 15%。脑间变性癌症和胶质母细胞瘤的预后仍然极差，预期生存率极低，新的分子标记和治疗靶点至关重要。表观遗传变化构成了开发新诊断和治疗策略的广阔领域。组蛋白乙酰转移酶-1 (HAT1) 已成为不同恶性肿瘤的潜在预后标志物和治疗靶点。数据存储库分析显示 HAT1 mRNA 在胶质瘤中过度表达，并且已描述了其在胶质母细胞瘤中的选择性剪接。使用免疫组织化学和适体化学方法，我们分析了 HAT1 在脑膜瘤、少突胶质细胞瘤和星形胶质细胞癌中的表达。我们观察到，HAT1 过度表达与最具侵袭性的肿瘤类型和较差的预后有关，并且与脑膜瘤早期复发的可能性较高有关。其胞质定位与肿瘤进展和预后相关。适体是能够结合和抑制多种靶标的合成寡核苷酸，被认为是有前途的诊断和治疗工具。与所使用的抗体相比，使用适体 apHAT610 进行的适体化学提供了更好的结果，这是适体作为组织病理学诊断工具潜力的一个很好的例子。

Primary malignancies of the central nervous system account for 2% of all cancers in adults and almost 15% in children under 15 years of age. The prognosis of brain anaplastic cancers and glioblastomas remains extremely poor, with devastating survival expectative, and new molecular markers and therapeutic targets are essential. Epigenetic changes constitute an extensive field for the development of new diagnostic and therapeutic strategies. Histone acetyl transferase-1 (HAT1) has merged as a potential prognostic marker and therapy target for different malignancies. Data repository analysis showed HAT1 mRNA overexpression in gliomas and has been described its alternative splicing in glioblastomas. Using immunohistochemical and aptahistochemical methods, we analyzed the expression of HAT1 in meningiomas, oligodendrogliomas, and astroglial cancers. We observed that HAT1 overexpression is associated with the most aggressive tumor types and the worse prognosis, as well as with a higher probability of early relapse in meningiomas. Its cytosolic localization correlates with tumor progression and prognosis. Aptamers, synthetic oligonucleotides capable to bind and inhibit a wide variety of targets, are considered as promising diagnostic and therapeutic tools. Aptahistochemistry using the aptamer apHAT610 offered superior results in comparison with the antibody used, as a good example of the potential of aptamers as diagnostic tools for histopathology.